Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05929079 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT05929079: Active Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT05929079 is a Phase 3 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,000 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05929079, a Phase 3 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- Excel Medical Clinical Trials - Boca Raton
- Teradan Clinical Trials, LLC - Brandon
- Fleming Island Center for Clinical Research - Fleming Island
- Therafirst Medical Center - Fort Lauderdale
- Clinical Site Partners LLC, dba Flourish Research - Miami
- Quantum Clinical Trials - Miami Beach
- Renstar Medical Research - Ocala
- Clinical Research Center of Florida - Pompano Beach
- Palm Beach Research Center - West Palm Beach
- Clinical Site Partners, LLC dba Flourish Research - Winter Park
California
- Core Healthcare Group - Cerritos
- Velocity Clinical Research, Westlake - Los Angeles
- Valley Clinical Trials, Inc. - Northridge
- Diablo Clinical Research, Inc. - Walnut Creek
Alabama
- Pinnacle Research Group, LLC - Anniston
- Cullman Clinical Trials - Cullman
Georgia
- NeuroTrials Research Inc - Atlanta
- Centricity Research Rincon Pulmonology - Rincon
Arkansas
- Preferred Research Partners - Little Rock
Connecticut
- Chase Medical Research, LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT05929079 still lists
NCT05929079 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (22% higher).
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05929079 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05929079 about?
NCT05929079 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight". The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study w...
What is the current status of trial NCT05929079?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2023-07-11. Estimated completion is 2026-05.
What conditions does trial NCT05929079 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight, Obstructive Sleep Apnea.
What interventions are being tested in trial NCT05929079?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT05929079?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05929079 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05929079's enrollment target sits among peer trials
1,000 73rd of 1053 higher than 978 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI